Am J Cancer Res 2022;12(6):2891-2892
www.ajcr.us /ISSN:2156-6976/ajcr0143539

Erratum
Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade: Am J Cancer Res. 2020; 10(2): 688-703

Hongzhi Li[1*], Weihua Yuan[2*], Shufang Bin[1], Guang Wu[1], Panyuan Li[1], Min Liu[3], Jifeng Yang[1], Xiang Li[1], Kaiyan Yang[4], Haihua Gu[1]

[1]Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China; [2]Department of Clinical Laboratory, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, Zhejiang, China; [3]Department of Orthopedics, Third Affiliated Hospital of Wenzhou Medical University, Wenzhou 325200, Zhejiang, China; [4]Department of Pathology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, Zhejiang, China. [*]Equal contributors.

Received April 14, 2022; Accepted May 11, 2022; Epub June 15, 2022; Published June 30, 2022

We recently have noticed mistakes in **Figure 7A**, in which the two negative control flow cytometry plots for BT474/Blank T and BT474/Blank T+anti-PD1 samples were inadvertently presented with the same image, and the two negative control plots for MB468/Blank T+anti-PD1 and HCC1954/Blank T+anti-PD1 samples were also carelessly presented with the same image during the assembly of the figures for publication. In addition, the flow plot for MB-468/Blank T sample was misplaced, which should be the correct image for the MB468/Blank T+anti-PD1 sample. Therefore, we have corrected the image for the MB468/Blank T+anti-PD1 sample. Furthermore, images for MB468/Blank T and BT474/Blank T samples have been replaced with the right flow plots accordingly in the corrected **Figure 7A**. We have also recalculated the data for **Figure 7B**, which essentially looks the same as before. Corrections for these flow plots do not affect the interpretation of **Figure 7**, and the conclusion of this study.

Address correspondence to: Drs. Hongzhi Li and Haihua Gu, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Chashan University Town, Wenzhou 325035, Zhejiang Province, China. Tel: +86-13676762210; E-mail: lhz@wmu.edu.cn (HZL); Tel: +86-15058751720; E-mail: haihuagu@wmu.edu.cn (HHG)



Figure 7. Anti-PD1 antibody decreases apoptosis of anti-HER2 CAR-T cells induced by HER2-positive breast cancer cells. (A) Blank T cells or anti-HER2 CAR-T cells were co-cultured in the absence or presence of anti-PD1 antibody with the indicated target cells at the effector: target ratio of 4:1 for 72 hours, then subjected to apoptosis analysis by flow cytometry analysis using Annexin V and 7-AAD reagents. Percentages of positive cells were shown in each quadrate. (B) Quantification of the flow cytometry analysis data from (A). The mean values from three different experiments were presented. CAR-T group was compared with blank T group, or CAR-T plus anti-PD1 group was compared with blank T plus anti-PD1 group, or CAR-T plus anti-PD1 group was compared with CAR-T group, $^{*}P<0.05$, $^{**}P<0.01$ and $^{***}P<0.001$.